Industry News
Biotechnology Industry News
Novo Nordisk has found a buyer for…
Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality.
Cancer imaging company Kuva Labs…
Cancer imaging company Kuva Labs is expanding its scope via the acquisition of solid tumor biotech Lisata Therapeutics.
Only four months after IO Biotech…
Only four months after IO Biotech decided to halve its head count, the Danish biotech is already considering whether it must resort to further layoffs.
AI-powered drug developer Insilico…
AI-powered drug developer Insilico Medicine is set for a $10 million upfront payment from a fresh-faced Chinese biotech for half of the rights to a brain-penetrant NLRP3 inhibitor.
For the second year in a row,…
For the second year in a row, flashes of pink cut through the sea of navy, gray and black that flooded San Francisco’s Union Square during the J.P. Morgan Annual Healthcare Conference. The color—largely worn
Riding a regulatory win for its…
Riding a regulatory win for its base editing candidate, Beam Therapeutics is “putting all of our eggs” in the in vivo delivery basket, CEO John Evans said.
Two former executives at Spero…
Two former executives at Spero Therapeutics have agreed to settle with the Securities and Exchange Commission for allegedly misleading investors about the efficacy of the biotech’s lead antibiotic candidate, with a total fine of $187,500.
Tanabe Pharma America’s small…
Tanabe Pharma America’s small molecule designed to boost melanin production has hit the main goal of a phase 3 trial for patients with rare hereditary disorders that cause extreme sensitivity to sunlight.
Pfizer is paying $30 million to…
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the pharma’s vaccine programs, with hundreds of millions of dollars in potential milestones tied to the deal.
Boundless Bio has finally given up…
Boundless Bio has finally given up on its hopes of finding redemption for two solid tumor drugs that had both come up short in the clinic by packaging them up as a combination treatment.
Adding Merck & Co. and…
Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they close in on
GSK is paying $2.2 billion to buy…
GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions.
The therapy in question, dubbed…
The therapy in question, dubbed C-CAR031, is based on AstraZeneca’s own GPC3-targeting CAR-T.
Immunology biotech Agomab…
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in the latest sign that the IPO window is reopening in 2026.
Vedanta Biosciences has…
Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria cocktail program.
ImmunityBio has reported ongoing…
ImmunityBio has reported ongoing complete responses of up to 15 months in two recipients of its CAR-NK cell therapy, leading the biopharma to talk up the prospects of the off-the-shelf blood cancer treatment.
The leaders of Chugai…
The leaders of Chugai Pharmaceutical are tired of their company not getting its due. At the J.P. Morgan Healthcare Conference in San Francisco, they’re working hard to change that while also seeking out new science
iRegene’s NouvNeu001 earns dual…
iRegene’s NouvNeu001 earns dual FTD/RMAT status, a first for iPSC therapies. Strong Phase I data in PD validates its scalable chemical induction platform.
After last year’s upheaval at…
After last year’s upheaval at the CDC’s Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy, Jr. is not done filling out the panel. The secretary this week added two OB-GYNs to the panel
Ocugen has reported preliminary…
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis and Astellas.